LPA Gene Coronary artery disease, susceptibility to NGS Genetic Test
Short Name: LPA Gene CAD NGS Test
Also known as: LPA Gene Variant Analysis, Lipoprotein(a) Gene Sequencing, LPA NGS Sequencing Test, Coronary Artery Disease Genetic Susceptibility Test
LPA Gene Coronary artery disease, susceptibility to NGS Genetic Test test available at DNA Labs India for ₹20,000. Uses Next-Generation Sequencing (NGS) on Blood or Extracted DNA or One drop Blood on FTA Card samples. Results in 3 to 4 Weeks from sample collection. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr SULOCHANA HEMCHANDRA HOLLA
Consultant Medical Geneticist · Reg: 8532
Last updated: September 7, 2026
Overview
The purpose of the LPA Gene Coronary Artery Disease Susceptibility NGS Genetic Test is to identify genetic variants in the LPA gene that may be associated with an elevated risk of developing coronary artery disease. This test uses next-generation sequencing technology to detect variants that influence lipoprotein(a) levels and atherosclerotic plaque formation. The results help clinicians assess an individual's genetic predisposition to CAD, guide preventive strategies, and inform decisions regarding lipid-lowering therapies, lifestyle modifications, and cardiac monitoring. NGS genetic DNA test detecets for variant and mutation detection in LPA gene for Coronary artery disease, susceptibility to
- Test Code
- 1961
- Price
- ₹20,000
- Sample Type
- Blood or Extracted DNA or One drop Blood on FTA Card
- Result Time
- 3 to 4 Weeks from sample collection
- Fasting Required
- No
- Method
- Next-Generation Sequencing (NGS)
Coronary artery disease (CAD) is a leading cause of death worldwide. It is a condition where plaque builds up in the arteries that supply blood to the heart, leading to a reduction in blood flow. The risk of developing CAD is influenced by a combination of environmental and genetic factors. One of the genes that have been linked to an increased risk of developing CAD is the LPA gene.
What is the LPA Gene?
The LPA gene provides instructions for making a protein called lipoprotein(a) or Lp(a). Lp(a) is a type of low-density lipoprotein (LDL) cholesterol that is associated with an increased risk of developing CAD. Lp(a) can accumulate in the walls of arteries and contribute to the formation of plaque.
How does the LPA Gene Affect the Risk of Developing CAD?
Studies have shown that people who have a variant of the LPA gene that produces high levels of Lp(a) are at an increased risk of developing CAD. In fact, having high levels of Lp(a) can increase the risk of CAD by up to 70%.
Diagnosis of LPA Gene and CAD
The diagnosis of LPA gene and CAD is typically made through a combination of clinical evaluation, imaging tests, and genetic testing. Symptoms of CAD may include chest pain, shortness of breath, and fatigue. Imaging tests such as a coronary angiogram or a cardiac CT scan can help determine the extent of plaque buildup in the arteries. Genetic testing can be used to identify variants in the LPA gene that may increase the risk of CAD.
NGS Genetic DNA Test for LPA Gene and CAD
Next-generation sequencing (NGS) is a powerful tool that can be used to identify genetic variants that may increase the risk of CAD. NGS technology allows for the sequencing of large amounts of genetic data quickly and accurately. This technology can be used to identify variants in the LPA gene that may be associated with an increased risk of CAD.
Cost of NGS Genetic DNA Test for LPA Gene and CAD
The cost of an NGS genetic DNA test for the LPA gene and CAD can vary depending on the provider and the specific tests that are performed. On average, the cost of an NGS genetic DNA test for LPA Gene and CAD in India is around INR 20,000.
Conclusion
The LPA gene has been linked to an increased risk of developing CAD. Genetic testing using NGS technology can be used to identify variants in the LPA gene that may increase the risk of CAD. Early identification of genetic variants associated with CAD can help individuals take steps to reduce their risk of developing this condition. If you have a family history of CAD or are experiencing symptoms of this condition, talk to your healthcare provider about the possibility of genetic testing.
Sample Collection
A genetic counselling session is recommended prior to sample collection to draw a pedigree chart of family members affected with coronary artery disease and to discuss the implications of genetic testing.
Method: Venipuncture / FTA Card
Laboratory Analysis
A blood sample of 3-5 mL will be collected via venipuncture into an EDTA tube, or alternatively a drop of blood can be collected on an FTA card. The procedure takes approximately 5-10 minutes.
Report Delivery
The sample will be transported to the laboratory under appropriate conditions. Results will be available within 3 to 4 weeks. A genetic counselling session is recommended post-testing to interpret the results and discuss next steps.
Timeline: 3 to 4 Weeks from sample collection
Patient Instructions
About This Test
Who Should Get This Test
The purpose of the LPA Gene Coronary Artery Disease Susceptibility NGS Genetic Test is to identify genetic variants in the LPA gene that may be associated with an elevated risk of developing coronary artery disease. This test uses next-generation sequencing technology to detect variants that influence lipoprotein(a) levels and atherosclerotic plaque formation. The results help clinicians assess an individual's genetic predisposition to CAD, guide preventive strategies, and inform decisions regarding lipid-lowering therapies, lifestyle modifications, and cardiac monitoring.
NGS genetic DNA test detecets for variant and mutation detection in LPA gene for Coronary artery disease, susceptibility to
How to Prepare
- No fasting is required prior to sample collection
- Maintain the blood sample at ambient room temperature during transport
- Ensure the EDTA tube is properly labeled with patient details
- If using an FTA card, allow the blood drop to dry completely before packaging
- Bring relevant clinical history and family pedigree information if available
Doctor's Notes
Reviewed by Dr SULOCHANA HEMCHANDRA HOLLA — MBBS, MD (Medical Genetics) · Reg. No. 8532
"Genetic variants in the LPA gene can significantly influence an individual's lifetime risk of coronary artery disease. NGS-based testing allows us to identify these variants early, enabling preventive strategies such as lifestyle modifications, lipid-lowering therapies, and closer cardiac monitoring. I recommend this test for patients with a strong family history of premature CAD or unexplained elevated cardiovascular risk despite normal lipid profiles."
Last updated: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Sample received without proper labeling or patient identification
- Insufficient sample volume for DNA extraction
- Severely hemolyzed or contaminated blood sample
- Sample received in a leaking or damaged container
- Sample collected in incorrect anticoagulant tube (non-EDTA)
Understanding Your Results
No clinically significant variant in the LPA gene was identified. This result does not eliminate CAD risk, as environmental factors and other genetic variants may still contribute.
Standard CAD risk management based on conventional risk factors
A variant associated with increased Lp(a) levels and CAD risk was identified in one copy of the LPA gene. This may indicate an elevated genetic susceptibility to coronary artery disease.
Enhanced cardiovascular monitoring, lipid management, and preventive interventions recommended
A variant associated with increased Lp(a) levels and CAD risk was identified in both copies of the LPA gene. This may indicate a significantly elevated genetic susceptibility to coronary artery disease.
Aggressive cardiovascular risk reduction strategies, specialist cardiac monitoring, and family screening recommended
A genetic change in the LPA gene was identified, but current evidence is insufficient to classify it as pathogenic or benign. Further evaluation and periodic reclassification may be needed.
Clinical correlation required; consider repeat analysis or additional testing as new evidence becomes available
Consult your healthcare provider or cardiologist if your test results indicate the presence of a pathogenic or likely pathogenic variant in the LPA gene. Additionally, seek medical advice if you have a family history of premature coronary artery disease, are experiencing symptoms such as chest pain, shortness of breath, or fatigue, or wish to discuss preventive strategies and treatment options based on your genetic risk profile.
Limitations
- ⚠This test identifies variants in the LPA gene only and does not assess all genetic contributors to coronary artery disease
- ⚠Detection of a pathogenic variant indicates increased susceptibility but does not confirm that CAD will develop
- ⚠A negative result does not eliminate the risk of CAD, as environmental and other genetic factors also contribute
- ⚠Some variants of uncertain significance (VUS) may be detected, which require periodic reclassification as new evidence emerges
- ⚠This test is not a diagnostic test for coronary artery disease and should be used alongside clinical evaluation
Risks & Considerations
- ●Minor bruising or discomfort at the venipuncture site
- ●Very small risk of infection at the blood draw site
- ●Emotional impact of genetic risk information — genetic counselling is recommended
Interfering Factors
- ●Recent blood transfusions may affect DNA analysis results
- ●Contaminated or degraded DNA samples may yield inconclusive results
- ●Hemolyzed blood samples may impact DNA extraction quality
- ●Use of certain anticoagulants other than EDTA may interfere with sample processing
Compare With Similar Tests
| Test | LPA Gene Coronary artery disease, susceptibility to NGS Genetic Test | |||
|---|---|---|---|---|
| Comparison | LPA Gene Coronary artery disease, susceptibility to NGS Genetic Test |
Frequently Asked Questions
What is the LPA Gene Coronary Artery Disease NGS Genetic Test?
Who should consider taking this test?
What sample is required for this test?
How long does it take to get the results?
What does it mean if a pathogenic variant is detected in the LPA gene?
Does a negative result mean I will not develop coronary artery disease?
Is genetic counselling included with this test?
What is lipoprotein(a) or Lp(a)?
Is this test covered by insurance in India?
Is home sample collection available for this test?
Can this test diagnose coronary artery disease?
What should I do if my results show an increased genetic risk for CAD?
Related Tests
MMC (Maternal Myopathy with Cardiomyopathy) Mutation Detection Test
₹11,500ITIH4 Gene Hypercholesterolemia, susceptibility to NGS Genetic Test
₹20,000PPP1R17 Gene Hypercholesterolemia, susceptibility to NGS Genetic Test
₹20,000APOA1 Gene Hypoalphalipoproteinemia NGS Genetic Test
₹20,000GJC2 Gene Lymphedema, hereditary, type IC NGS Genetic Test
₹20,000RYR2 Gene Arrhythmogenic right ventricular dysplasia type 2 NGS Genetic Test
₹20,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.